Introduction {#sec1-1}
============

Morbidity and mortality due to invasive fungal infections (IFIs) remain high in children with cancer treated with intensive protocols. Mortality due to IFIs have been reported to be as high as 18% ([@ref1]); therefore, precise diagnosis and treatment are crucial. In this paper, we report a child with acute lymphoblastic leukemia (ALL), who presented only with mild pain in the orbital area. He was diagnosed as having mucor and successfully treated with antifungal agents and surgery for orbital mucormycosis.

Case {#sec1-2}
====

An 8-year-old boy was treated for moderate risk precursor B cell ALL with a BFM-ALL protocol. At the end of the first phase of delayed intensification (protocol II), he was hospitalized with febrile neutropenia. Intravenous (iv) cefepime was initiated empirically. At 48 hours, fever continued and the patient began to report mild pain in the left orbita. No abnormality was detected in examinations by an ophthalmologist and otolaryngologist. No microbiologic agent was detected in blood cultures. Galactomannan tests were negative in serum. Magnetic resonance imaging (MRI) revealed lesions consistent with infection in the sphenoidal, mastoid, and ethmoid sinuses extruding the left periorbital area. Considering a fungal infection, iv voriconazole was initiated, and after a day, high fever persisted (40°C) and a periorbital swelling was observed. Intravenous liposomal amphotericin B was added to antifungal therapy because we could not rule out a mucormycosis infection.

After five days, fever continued and MRI signs of progressive infection and periorbital abscess formation ([Fig. 1](#F1){ref-type="fig"}) was observed on the same day. Surgical drainage was performed and an absorbable gelatin sponge containing liposomal amphotericin B was inserted locally. Fever subsided in 24 hours. No pathogen was detected in cultures. Mucormycosis was diagnosed by pathology on the surgical drainage material. Chemotherapy was initiated again. Liposomal amphotericin B was continued during delayed intensification and the first month of ALL maintenance treatment for a total of 74 days (2.5 months). Treatment was switched to posaconazole during the continuation of ALL maintenance treatment, which continued at home, because the spectrum of posaconazole covers mucormycosis and it is taken orally. Oral posaconazole was given for a total of six months during the maintenance treatment. The patient has remained in remission for ALL and free of fungal infection for a total of four years from diagnosis. Informed consent was obtained from the parents of the patient who participated in this study.

![Magnetic resonance imaging revealed lesions consistent with infection in the left maxillar and ethmoid sinuses and left periorbital abcess formation](TPA-55-207-g001){#F1}

Discussion {#sec1-3}
==========

The diagnosis of mucormycosis is difficult and demanding. Treatment should start as soon as possible to decrease morbidity and mortality if there is a suspicion for mucormycosis. No specific antigen detecting test is available.

Prolonged and severe neutropenia, prolonged high-dose systemic corticosteroids, colonization by Mucorales, and either heavy environmental exposure or previous exposure to antifungal agents are reported as important risk factors for mucormycosis.

The treatment of mucormycosis includes antifungal agents, surgical debridement, and correction of the underlying disease predisposing the patient to mucormycosis. The European Conference on Infections in Leukemia (ECIL 3) recommends liposomal amphotericin B or amphotericin B lipid complex as first-line treatment for mucormycosis (BII). The duration of antifungal treatment should be considered for each patient individually, but treatment should usually continue for at least 6-8 weeks. The crucial point, which is as important as the duration of therapy, is the prompt initiation of the antifungal therapy. In our patient, the suspicion for an oculoorbital and paranasal infection only due to mild pain without any pathologic findings in the ophthalmologic and otolaryngologic examinations, led us to an early diagnosis.

Posaconazole has been reported to be effective in patients with mucormycosis who are refractory to or intolerant of liposomal amphotericin B or who need maintenance treatment (BII) ([@ref2], [@ref3]). In our case, posaconazole was used during the maintenance chemotherapy phase so that the patient could be treated orally at home, thus leading to a better quality of life.

The importance of surgery has been demonstrated in case series. A single-center study analyzing the impact of combination antifungal therapy for rhino-orbito-cerebral mucormycosis in 41 patients reported that all patients had at least one surgical intervention, showing that the standard approach includes surgical intervention when appropriate ([@ref4]). In a recent study reviewing 90 patients with rhino-orbito-cerebral mucormycosis and solid organ transplantation, surgical debridement was found to be independently associated with improved outcomes ([@ref5]).

Gupta et al. ([@ref6]) reported two patients with ALL with mucormycosis in whom successful results were observed with surgical debridement and amphotericin B therapy. Tuysuz et al. ([@ref7]) presented a 9-year-old boy with ALL and hepatic mucormycosis. Despite the use of liposomal amphotericin B and posaconazole therapy in combination for a long duration, the lesion persisted and it was treated through surgical excision.

In our case, there was no clinical or radiologic improvement despite specific systemic antifungal treatment in five days. However, fever subsided significantly within 24 hours after surgery, suggesting the importance of surgery in these cases. Also, there were no sequelae in the long-term follow-up.

Mucormycosis should be in the differential diagnosis in infections in children with cancer, especially leukemia, according to clinical and radiologic findings. A high degree of suspicion and prompt systemic empirical antifungal therapy, as well as surgical debridement, are crucial for the survival of patients.
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[^1]: **The known about this topic**

    Mucormycosis in pediatric patients with hematological and oncological malignancies is a rare invasive fungal infection associated with significant morbidity and mortality. Despite the published guidelines on the management of this infection, there is a lack of data on the importance of multidisciplinary approach, including when it is safe to resume chemotherapy and the timing of surgical debridement.

[^2]: **Contribution of the study**

    In our paper, we emphasized that rapid diagnosis and a multidisciplinary approach can lead to excellent outcomes, even in patients undergoing intensive chemotherapy and we would like to raise awareness of mucormycosis during induction therapy for pediatric acute lymphoblastic leukemia.
